Literature DB >> 22124213

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

K H Metzeler, A Walker, S Geyer, R Garzon, R B Klisovic, C D Bloomfield, W Blum, G Marcucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22124213      PMCID： PMC3696987          DOI： 10.1038/leu.2011.342

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  MutationTaster evaluates disease-causing potential of sequence alterations.

Authors:  Jana Marie Schwarz; Christian Rödelsperger; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2010-08       Impact factor: 28.547

2.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

Authors:  J G Herman; C I Civin; J P Issa; M I Collector; S J Sharkis; S B Baylin
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Peter Paschka; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

6.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Kati Maharry; Michael D Radmacher; Heiko Becker; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Yue-Zhong Wu; Sebastian Schwind; Klaus H Metzeler; Jing Wen; Maria R Baer; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Joseph O Moore; Richard M Stone; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

7.  Array-based genomic resequencing of human leukemia.

Authors:  Y Yamashita; J Yuan; I Suetake; H Suzuki; Y Ishikawa; Y L Choi; T Ueno; M Soda; T Hamada; H Haruta; S Takada; Y Miyazaki; H Kiyoi; E Ito; T Naoe; M Tomonaga; M Toyota; S Tajima; A Iwama; H Mano
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

Review 9.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

10.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717
View more
  84 in total

1.  Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.

Authors:  Celeste Holz-Schietinger; Doug M Matje; Norbert O Reich
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

2.  Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Authors:  F Ostronoff; M Othus; P A Ho; M Kutny; D E Geraghty; S H Petersdorf; J E Godwin; C L Willman; J P Radich; F R Appelbaum; D L Stirewalt; S Meshinchi
Journal:  Leukemia       Date:  2012-06-22       Impact factor: 11.528

Review 3.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

Review 4.  The artful management of older patients with acute myeloid leukemia.

Authors:  Jay Yang; Charles A Schiffer
Journal:  Expert Rev Hematol       Date:  2016-03-02       Impact factor: 2.929

Review 5.  Why methylation is not a marker predictive of response to hypomethylating agents.

Authors:  Maria Teresa Voso; Valeria Santini; Emiliano Fabiani; Luana Fianchi; Marianna Criscuolo; Giulia Falconi; Francesco Guidi; Stefan Hohaus; Giuseppe Leone
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 6.  Treatment of Elderly Patients With Acute Myeloid Leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 7.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 8.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

9.  Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Authors:  Daniel A Pollyea; James Zehnder; Steve Coutre; Jason R Gotlib; Leonel Gallegos; Omar Abdel-Wahab; Peter Greenberg; Bing Zhang; Michaela Liedtke; Caroline Berube; Ross Levine; Beverly S Mitchell; Bruno C Medeiros
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 10.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.